These 3 stocks are prepared for a brief increase in pressure in 2025

Retail merchants are once again stirring the pot in very short capitalization shares, a family pattern for those who saw the explosive manifestations of recent years. While the chaos of the previous races driven by memes has cooled, the ingredients for another break, the fleets of the lamb, a high interest and the sudden peaks in the volume of commerce) are being reassembled silently.

Several lower price names with unusually large short positions have begun to show an unusual movement on the tape. Many exchange less than $ 20 per share and are found in the market capitalization range of less than $ 2 billion, which makes them ideal configurations for volatility.

Among the multitude of speculative works, three actions have arisen with a strong bearish pressure and a growing attention of opportunistic merchants.

Airshulpt Technologies (Nasdaq: Airs)

MARKET CAUT: $ 388.5 million
Brief interest: 53.1%
YTD performance: +13.9%

Anestulpt Technologies, which operates under the sculpture mark of the elite body, specializes in minimally invasive fat recovery procedures using its Airsculpt® patented method. The company offers contours of the cosmetic body for customers looking for alternatives to traditional liposuction.

Despite the modest profits of shares prices this year, Airsesculpt is deeply short: more than half of its float is currently maintained in short positions. That is the highest level among all qualified actions. The action fell abruptly after its profit failure of the second quarter and the announced retirement of its long -standing CFO, Dennis Dean. In the last nine quarters, the company has only published a profit rate.

The Management maintained its 2025 guide, projecting revenues between $ 160 million and $ 170 million, and an adjusted Ebitda of $ 16-18 million. But analysts are still cautious. With only three covering the actions, everyone has issued a “retention” rating. The average target price is $ 4.50, which suggests that even with the current price premium, few expect short -term rise according to the foundations alone.

However, in a market increasingly driven by positioning and feeling, not only the foundations, the level of short interest may be sufficient to attract impulse merchants.

The Children’s Place (Nasdaq: PLCE)

MARKET CAUT: $ 106.5 million
Brief interest: 50.2%
YTD performance: –56.6%

A family name for American buyers, The Children’s Place has been in retail trade since 1969, but its business has been drastically reduced in recent years. Known for clothing for children with headquarters in the mall, the company also has brands such as Gymboree and PJ Place. But the weak demand, the increase in costs and the closure of stores have left the retailer in considerable stress.

Net losses were extended in the most recent quarter, with a decrease in income year after year 9.6%. The company recorded a loss of $ 1.52 per share for the first quarter of 2025, deeper than the previous year of $ 1.18. The store count also fell to 495 locations, below 518 a year ago. Despite the reduction of the net cash output of operations, the company remains under pressure with only $ 5.7 million in cash and more than $ 350 million in short -term debt.

The Wall Street coverage is thin. Only a company currently tracks PLCE, assigning it a “retention” rating with an objective of $ 6, which implies a limited rise, but there is also no strong case for a rebound. Even so, the short interest above 50% places the shares directly in the radar of the merchants seeking short tight opportunities, particularly given the historically thin flotation and the limited supervision of the analysts.

ZENAS BIOPHARMA (NASDAQ: ZBIO)

MARKET CAUT: $ 657.2 million
Brief interest: 50.1%
YTD performance: +88.2%

Zenas Biopharma can be the least familiar name on this list, but it is also the one that shows the clearest signs of investors beyond the technical configurations. The company is a clinical stage biotechnology company focused on immunology and autoimmune treatments. Its pipe, although in the initial stage, has attracted the attention of analysts and institutions equally.

The public trade history of Zbio is short, the company that appears at the end of 2024, and its profit history is limited. In its first complete quarter as a public company, Zenas registered $ 10 million in income and a closer loss of the expected $ 0.80 per share (analysts expected: $ 1.13). The cash burn grew to $ 37 million in the first quarter, but the company finished the quarter with a substantial reserve of $ 196.5 million, easily covering its liabilities in the short term.

Unlike the other two names, Zenas has strong support from analysts. The six companies that cover the shares have issued a “strong purchase” rating. The target consensus price is $ 32.33, which represents an increase of more than 100% of the current levels.

With a legitimate product pipe, deep funds and a considerable short interest, Zbio stands out as a possible battlefield between bears that bet on delay and dilution, and bulls position for the impulse of the clinical trial.

Low limits, high risk, growing interest

Each of these companies (Asparbulpts, Children’s Place and Zenas Biopharma) reflects a different type of pressure point in the current market. One is sailing for weak profits in the midst of executive billing. Another is to bring a great debt against the reduction of commercial space. The third is a clinical stage biotechnology without profits, but a lot of investor speculation.

What UNE is not the sector or strategy, but the structure: the three are below $ 20 per share, they have higher market limits and are among the shortest actions in the public market. For investors that track short interest as a signal, these names already show early signs of high volatility. If that translates into sustained movements or fleeting peaks, it depends less on feeling, and more than what appears in the next earning calls, product update or 13F presentation.

Also read: 3 cybersecurity actions that earn attention after the problem of the SharePoint server